|
|||||
|
|
Brivaracetam,a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action |
|
| Authors: | Jean‐Marie Nicolas Jonas Hannestad Daniel Holden Sophie Kervyn Nabeel Nabulsi Yiyun Huang Hugues Chanteux Ludovicus Staelens Alain Matagne François‐Xavier Mathy Joël Mercier Armel Stockis Richard E. Carson Henrik Klitgaard |
| Affiliation: | 1. UCB Pharma, Braine l'Alleud, Belgium;2. PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut, U.S.A. |
| Abstract: | |
| Keywords: | Brivaracetam Levetiracetam Blood– brain barrier Physiologically based pharmacokinetic Status epilepticus Onset of action |